Hostname: page-component-cd9895bd7-7cvxr Total loading time: 0 Render date: 2024-12-26T22:55:20.870Z Has data issue: false hasContentIssue false
  • English
  • Français

The Disappointment of the Biosimilar

Published online by Cambridge University Press:  01 January 2021

Jeremy A. Greene
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Independent Articles: Commentary
Information
Journal of Law, Medicine & Ethics , Volume 46 , Issue 3: The Medicalization of Poverty; Perspectives of Alzheimer's Disease: Ethical, Legal, and Social Issues , Fall 2018 , pp. 791 - 793
Copyright
Copyright © American Society of Law, Medicine and Ethics 2018

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Herber, M., “The first drug with a $1 million price tag is already on the market,” Forbes, May 1, 2018, available at <https://www.forbes.com/sites/matthewherper/2012/05/01/the-first-drug-with-a-1-million-price-tag-is-already-on-the-market/#7bb318baabde> (last visited August 2, 2018).+(last+visited+August+2,+2018).>Google Scholar
Diependaele, L. et al., “Similar or the Same? Why Biosimilars are not the Solution,” Journal of Law, Medicine & Ethics 46, no. 3 (2018): 776-790.CrossRefGoogle Scholar
Beran, D., Hirsch, I. B., and Yudkin, J. S., “Why are we Failing to Address the Issue of Access to Insulin? A National and Global Perspective,” Diabetes Care 41, no. 6 (2018): 1125-1131.Google Scholar
Heinemann, L., “Biosimilar Insulins: How will this Story Evolve?” Diabetes Technology & Therapeutics 14 (2012):986-988.Google Scholar
Greene, J.A., Generic: The Unbranding of Modern Medicine (Baltimore: Johns Hopkins University Press, 2014).Google Scholar
Engelberg, A.B., “Special Patent Provisions for Pharmaceuticals: Have They Outlived Their Usefulness,” Specialty Law Digest: Health Care Law 258 (2000):9-48.Google Scholar